Abstract Purpose: The purpose of this research was to compare methylation status and mRNA expression of p15
with each other (P < 0.001), the methylation status did not seem to be linked with levels of mRNA expression, as no association between the two events was found for either gene. Promoter hypermethylation of p15
INK4b was more common in ovarian cancer (30.8% for the 52 cases) than in normal ovaries (5% for the 40 controls without ovarian cancer; P = 0.005) but not methylation of p16
INK4a (25% for cancer versus 37.5% for normal; P = 0.288). The relative mRNA expression levels of p15
INK4b were significantly lower in ovarian cancer (12.9%) than in normal ovaries (41.7%; P = 0.008) but not those of p16 INK4a (27% for cases versus 32.8% for controls; P = 0.754). Only high methylation rate and low mRNA expression of p15
INK4b were independent risk factors for ovarian cancer (adjusted odds ratio, 5.67; 95% confidence interval, 0.85-37.9 for high methylation rate and odds ratio, 8.98; 95% confidence interval, 1.58-50.9 for low mRNA expression, respectively).
Conclusions: Our results suggest that epigenetic alterations in p15
INK4b but not p16 INK4a have an important role in ovarian carcinogenesis and that mechanisms other than methylation may exist to reduce gene expression of p15
INK4b in ovarian cancer.
Ovarian cancer remains a major threat to women's health in the United States. It was estimated that, in 2004, f25,580 women would be diagnosed with and 16,090 would die from ovarian cancer (1) . Because of the inability to detect ovarian cancer at an early, more curable stage, its survival rate has been essentially unchanged over the past 20 years. Early detection and prevention, therefore, depend on the ability to identify genetic and epigenetic events that underlie the development and progression of ovarian cancer.
Epigenetic events, such as de novo cytosine-DNA methylation at CpG sites in the promoter region, can alter mRNA expression, one of the phenotypic characteristics of tumor development and progression (2) . Mounting evidence suggests that aberrant methylation of CpG islands is one of the major pathways involved in the inactivation of tumor suppressor genes and the development of cancer (3) . Indeed, several types of cancer, including ovarian cancer, exhibit a methylation phenotype (4, 5) . In particular, certain types of tumors, including ovarian cancer, show aberrant methylation of CpG islands in the promoter regions of tumor suppressor genes, including the p15 INK4b (6) and p16 INK4a (7, 8) . Both p15
INK4b and p16
INK4a proteins are inhibitors of cyclin-dependent kinases that prevent the cell from going through the G 1 -S phase transition; therefore, inactivation of p15
INK4b and p16
INK4a is thought to be an important step in cancer development (6 -9) . p15
INK4b and p16 INK4a promoter methylation has been reported in several types of primary tumors and cancer cell lines, including acute myeloid leukemia (6, 10, 11) and cancer of the lung (4, 6, 12) , breast (4, 6, 13) , bladder (4, 14) , head and neck (6, 15, 16) , prostate (6), colon (6), liver (17) , kidney (18) , and stomach (19) .
Several studies of the methylation status of p15 INK4b and p16
INK4a in ovarian cancer have been published (20 -23) . Whether either gene is aberrantly methylated in ovarian cancer is still controversial, particularly in the most common form of serous epithelial ovarian cancers. However, at least one study reported an association between methylation of p16
INK4a and disease progression, suggesting that an understanding of the regulation of methylation and the expression of p16
INK4a is critical to future management strategies for ovarian cancer (8) . Thus, although it is clear that the expression of p15
INK4b or p16
INK4a is aberrant in ovarian cancer, it is not clear whether methylation contributes to the alterations in gene expression or whether these two events are independent in ovarian carcinogenesis. Therefore, the role of de novo DNA methylation in ovarian cancer remains uncertain.
We hypothesized that cytosine-DNA methylation differentially regulates the expression of p15
INK4b and p16 INK4a , and these differences may play a differential role in the processes contributing to ovarian tumorigenesis. Here, we report the methylation status and mRNA expression of both p15
INK4b
and p16
INK4a in serous epithelial ovarian cancer tissue specimens from 52 patients compared with 40 apparently normal ovarian tissue samples from different individuals without ovarian cancer. Methylated CpG islands in the promoters of p15
INK4b and p16 INK4a were detected by methylation-specific PCR (MSP) and compared with levels of mRNA expression in the same individuals measured by real-time reverse transcription-PCR. Anderson Cancer Center, tumor tissues were obtained from 52 patients with newly diagnosed primary serous ovarian carcinoma. Control specimens came from two sources: from apparently normal contralateral ovaries of 8 patients with unilateral ovarian cancer and from 40 other patients, of whom 27 underwent surgery for nonovarian cancer (9 with endometrial cancer, 11 with cervical cancer, 6 with uterine cancer, and 1 appendix mucinous tumor) and 13 for benign conditions (9 endometriosis, 2 cervical hyperplasia, 1 fallopian paratubal cysts, and 1 unknown). All samples were snap frozen after surgical removal, stored at À80jC, and tested after pathologic examination. DNA and RNA were extracted from f200 mg of fresh frozen tissue specimens. Informed consent was obtained from each patient, and the study was approved by M.D. Anderson Cancer Center institutional review board.
Materials and Methods
Methylation-specific PCR. DNA was prepared by overnight digestion with 200 Ag/mL proteinase K (Life Technologies, Inc., Rockville, MD) at 42jC followed by phenol/chloroform (1:1) extraction and ethanol precipitation. We used MSP to examine the promoter methylation status of the p15
INK4b and p16 INK4a genes. Briefly, genomic DNA (1 Ag) was modified with sodium bisulfite by using a CpGenome DNA Modification kit according to the manufacturer's instructions (Serologicals Corp., Norcross, GA). The bisulfite-modified DNA (100 ng) was separately amplified by using primers specific for methylated p15 INK4b (forward GCGTTCGTATTTTGCGGTT and reverse CGTACAA-TAACCGAACGACCGA) and for unmethylated p15
INK4b (forward TGTGATGTGTTTGTATTTTGTGGTT and reverse CCATACAAT-AACCAAACAACCAA; Genbank accession no. S75756; ref. 24 ) as well as primers specific for methylated p16
INK4a (forward TTA-TTAGAGGGTGGGGCGGATCGC and reverse GACCCCGAA-CCGCGACCGTAA) and for unmethylated p16
INK4a (forward TTATTAGAGGGTGGGGTGGATTGT and reverse CAACCCCAAACCA-CAACCATAA; Genbank accession no. X94154; ref. 24) . For methylation detection, CpGenome Universal Methylated DNA (Serologicals) was used as the positive control for amplification of methylated alleles, and water blanks without added DNA were included as the negative PCR controls in each assay. DNA amplification was carried out by using reagents supplied in a HotStarTaq DNA Polymerase kit (Qiagen, Inc., Valencia, CA). The PCR mixture contained PCR buffer [16.6 mmol/L ammonium sulfate (pH 8. , 1 minute at the annealing temperature 60-65jC, and 1 minute at 72jC) followed by a final 10-minute extension at 72jC. PCR products were analyzed on 2% agarose gels containing ethidium bromide (Fig. 1) . The results were evaluated independently by two researchers, and samples with questionable results were retested to achieve agreement between observers.
Real-time reverse transcription-PCR for mRNA expression. Total RNA was extracted with Tri-Reagent according to the manufacturer's protocol (Molecular Research Center, Cincinnati, OH). We assessed the quality of the extracted total RNA on 1% agarose gels after electrophoresis by visualizing the 18S and 28S RNA bands under UV light (Fig. 2) , and RNA concentration was determined with the GeneQuant Pro RNA/ DNA Calculator (Amersham Pharmacia Biotech, Cambridge, United Kingdom) before it was used for assessment of mRNA levels. The primers and probes for detecting p15 INK4b , p16
INK4a , and GAPDH cDNA sequences (Genbank accession nos. XM_027626, XM_027621, and AK026525, respectively) were designed by using Primers Express software (Perkin-Elmer Applied Biosystems, Foster City, CA). They were forward CGTGGGAAAGAAGGGAAGAGT, reverse CCCCA-GACGCGCAGC, and probe FAM-CGGCCAACGGTGGATTATCCGG-TAMRA for p15
INK4b ; forward CTCACGCCCTAAGCGCA, reverse AGTCGACAGCTTCCGGAGG, and probe FAM-TCATGTGGG-CATTTCTTGCGAGCC-TAMRA for p16
INK4a ; and forward GAAGGT-GAAGGTCGGAGTC, reverse GAAGATGGTGATGGGATTTC, and probe FAM-CAAGCTTCCCGTTCTCAGCC-TAMRA for GAPDH (used as an internal control for relative quantification). The fluorogenic probes contained a reporter dye [FAM (6-carboxyfluorescein)] covalently attached at the 5V end and a quencher dye [TAMRA (6-carboxytetramethylrhodamine)] covalently attached at the 3V end. Total RNA from each sample (f50 ng) was used to quantify the cDNA copy number of p15 INK4b , p16
INK4a , and GAPDH. Reverse transcription-PCR was done by using the TaqMan One-Step Reverse Transcriptase-PCR Master Mix Reagents with an ABI PRISM 7700 Sequence Detection System according to the protocol of the manufacturer (Perkin-Elmer Applied Biosystems). The system detects the fluorescence emitted from the fluorogenic oligonucleotide probes, and the signal is directly proportional to the number of template molecules in the reaction mixture after they have crossed a fluorescence detection threshold (25) . The ABI PRISM 7700 Sequence Detector is a thermal cycler designed to monitor multiple fluorescent signals in a 96-well format. Samples were amplified in 96-well optical PCR trays and caps, and the data were directly collected during the cycling procedure. After activation of the AmpliTaq Gold at 48jC for 30 minutes and 95jC for 10 minutes, the samples were subjected to 40 cycles, each consisting of 95jC for 15 seconds and 60jC for 1 minute. The GAPDH signal was used as the internal control. The expression level of the target genes was calculated based on a standard curve established with a standard human RNA sample that contained a large number of copies to ensure the detection of GAPDH mRNA (f1 Â 10 5 copies/ng, Perkin-Elmer Applied Biosystems). The standard curve was constructed with a continuation of six data points equivalent to 50,000, 5,000, 500, 50, 5, and 0.5 pg of human RNA. Each sample was measured in triplicate and the means of the three values were calculated for statistical analysis. About 10% of the samples were retested using the same RNA samples, and the measurements were found to be consistent between repeats.
Statistical analysis. Student's t test was used to compare the differences in the relative mRNA expression levels, which were analyzed as a continuous variable between groups. The m 2 test was used to test associations between methylation status and risk for ovarian cancer, and the Pearson correlation coefficients were calculated for correlation analysis. For calculation of crude odds ratios (OR) and 95% confidence intervals (95% CI), the median relative expression level of p15
INK4a mRNA in the controls was used as the cutoff point for defining lower versus higher expression level. Adjusted ORs were calculated by fitting logistic regression models with adjustment for patient age and ethnicity and other variables of interest. All statistical analyses were done with SAS software version 8.0e (SAS Institute, Inc., Cary, NC).
Results

p15
INK4b and p16 INK4a methylation and expression in ovarian tumor and noncancerous ovarian tissues. Raw data on p15
INK4b
INK4a promoter methylation and relative mRNA expression levels in ovarian tumor specimens (the cases) are presented in Table 1 and those in normal ovary specimens (the controls) in Table 2 . The promoter methylation results are presented as either ''U'' for unmethylated or ''M'' for methylated. Overall, cases were older than controls (61.5 F 9.4 versus 50 F 11.5 years; P = 0.001), but no difference was found in the distribution of ethnic groups between cases (45 whites, INK4b and P = 0.716 for p16 INK4a among the controls). However, the relative mRNA expression levels of p15
INK4a were highly correlated with each other (r = 0.5 and P < 0.001 for the cases and r = 0.7 and P < 0.001 for the controls). When the 48 controls were stratified by their primary cancer status, the mean age was 49.3 F 11.9 years for those with ovarian cancer (n = 8), 52.2 F 12.5 years for those with cancers other than ovarian cancer (n = 27), and 46.1 F 8.4 years for those without any cancer (n = 13; Table 3 ).
The p15 INK4b methylation rate was higher among the 52 cases (31%) than among all 48 controls (6.3%; P = 0.004) and also higher than any of the control subgroups [8 with primary ovarian cancer (12.5%; P = 0.510), 27 with primary cancer other than ovarian (3.7%; P = 0.012), and 13 without cancer (7.8%; P = 0.178)]. In contrast, the p16
INK4a methylation rate seemed to be lower among the cases (25%) than among the controls (37.5% for all 48 controls, 37.5% for the 8 with unilateral ovarian cancer, 29.6% for the 27 with other cancers, and 53.9% for the 13 with no cancer), but none of the apparent differences was statistically significant (Table 3) . Because the 8 controls with unilateral primary ovarian cancer had a higher p15
INK4b methylation rate (12.5%) than the other controls, they were excluded from the control group. The final control group used for further case-control comparisons consisted of 40 subjects. Compared with the case group, the 40 subjects in this final control group were younger (49 years; P = 0.01), had a lower p15
INK4b methylation rate (5.0%; P = 0.05), and had a slightly higher p16
INK4a methylation rate (37.5%; P = 0.288; Table 3 ).
Consistent with the methylation data, the mean F SD relative p15
INK4b mRNA expression levels were lower among the 52 cases (12.9 F 41.2%) than among all 48 controls (40.4 F 56.9%; P = 0.05) and among the control subgroups [primary ovarian cancer (n = 8), 33.8 F 35.1%; P = 0.180, primary cancer other than ovarian cancer (n = 27), 32.2 F 47.4%; P = 0.065, and those without cancer (n = 13), 61.6 F 80.2%; P = 0.003]. Similarly, the p16
INK4a expression levels were generally lower among the cases (27.0 F 114%) than among the controls (31.9 F 67.0% for all 48 controls, 27.6 F 23.5% for the 8 with unilateral ovarian cancer, 20.7 F 32.3% for the 27 with other cancer, and 57.9 F 118.2% for the 13 with no cancer), but none of the apparent differences was statistically significant (Table 3 ). The final control group (n = 40) had higher levels of p15
INK4b expression (41.7 F 61.1%; P = 0.008) and slightly higher levels of p16
INK4a expression (32.8 F 27.0%; P = 0.754) than did those with ovarian cancer (Table 3) .
Association between risk for ovarian cancer and p15 INK4b and p16
INK4a methylation status and mRNA expression levels. We then performed logistic regression analysis that included known risk factors for ovarian cancer, such as age (in years) and ethnicity, and used methylation status and dichotomized mRNA expression levels [using the median relative mRNA expression levels of the final controls (n = 40) as the cutoff points (23.6% for p15
INK4b and 14.7% for p16 INK4a )]. We found that ovarian tumor tissues were more likely to have methylated p15
INK4b than normal ovarian tissues (age-and ethnicity-adjusted OR, 5.68; 95% CI, 1.14-28.2), but no such association was evident for p16 INK4a (adjusted OR, 0.47; 95% CI, 0.16-1.37; Table 4 ). Furthermore, low mRNA expression levels of p15
INK4b were associated with a >9-fold increased risk of ovarian cancer (adjusted OR, 9.04; 95% CI, 2.51-32.5); and, low mRNA expression levels of p16
INK4a were associated with f3-fold increase in risk of ovarian cancer (adjusted OR, 2.81; 95% CI, 1.04-7.62; Table 4 ). Although the 52 cases were substantially older than the 40 controls (a 10-year difference in the mean age), the ORs with and without adjustment for age and ethnicity (Table 4) did not change the results substantially, suggesting that age may not have a major effect on either methylation or mRNA expression levels in this study population.
Finally, to assess whether the risk for ovarian cancer associated with low mRNA expression of both p15
INK4a was independent, we fit all variables (age, ethnicity, and methylation status and expression levels of both p15
INK4b and p16 INK4a ) in one logistic regression model. We found that the risk for ovarian cancer was associated with both high methylation status (adjusted OR, 5.67; 95% CI, 0.85-37.9) and low mRNA expression levels (adjusted OR, 8 *Two-sided m 2 test. cAdjusted for age (in years) and ethnicity (non-Hispanic whites versus others) in a logistic regression model. bAdjusted for age (in years), ethnicity (non-Hispanic whites versus others), and each other by including all methylation and expression variables in the same logistic regression model. x The median relative mRNA expression level in the controls was used as the cutoff point for each gene.
